Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Marimed (MRMD) Acquisitions (2019 - 2025)

Marimed (MRMD) has disclosed Acquisitions for 5 consecutive years, with -$231000.0 as the latest value for Q1 2025.

  • On a quarterly basis, Acquisitions changed N/A to -$231000.0 in Q1 2025 year-over-year; TTM through Sep 2025 was -$231000.0, a 105.44% decrease, with the full-year FY2024 number at $4.2 million, up 42.28% from a year prior.
  • Acquisitions was -$231000.0 for Q1 2025 at Marimed, down from $4.2 million in the prior quarter.
  • In the past five years, Acquisitions ranged from a high of $4.2 million in Q2 2024 to a low of -$231000.0 in Q1 2025.
  • A 4-year average of $1.5 million and a median of $1.0 million in 2022 define the central range for Acquisitions.
  • Peak YoY movement for Acquisitions: plummeted 100.41% in 2023, then surged 53225.0% in 2024.
  • Marimed's Acquisitions stood at $101000.0 in 2022, then plummeted by 107.92% to -$8000.0 in 2023, then soared by 53225.0% to $4.2 million in 2024, then plummeted by 105.44% to -$231000.0 in 2025.
  • Per Business Quant, the three most recent readings for MRMD's Acquisitions are -$231000.0 (Q1 2025), $4.2 million (Q2 2024), and -$8000.0 (Q2 2023).